Cytori Therapeutics Company Profile (NASDAQ:CYTX)

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (290.24% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Roth CapitalReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015Ascendiant Capital MarketsInitiated CoverageBuy$18.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2015LaidlawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q4($0.04)($0.03)$1.56 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.03)($0.06)$2.50 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.11)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($7.35)($7.35)($7.35)
Q3 20161($7.05)($7.05)($7.05)
Q4 20161($8.25)($8.25)($8.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline
07/27/16 09:15 PMCytori Therapeutics (NASDAQ:CYTX) decreased -3.55%: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Vodafone ... - KC Register
07/25/16 06:18 AMWhat Do All These Investigator-Initiated Studies Mean to Cytori? - [at noodls] - Dear Stockholders - In recent months there has been a number of publications detailing the expanding research use of Cytori® Cell Therapy™ in disease states as varied as dental surgery, lymphedema, and ...
07/22/16 03:28 PMCytori Therapeutics, Inc. (NasdaqCM:CYTX) Fundamental Star Rating Report - CML News
07/22/16 07:18 AMCytori to Webcast Second Quarter Financial Results on August 4 - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 4, 2016 at 5:30 PM Eastern ...
07/20/16 08:52 AMPremarket Runners: Netflix, Inc. (NASDAQ:NFLX), Cytori Therapeutics Inc. (NASDAQ:CYTX) - Review Fortune
07/19/16 03:37 PMCytori Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration
07/19/16 11:16 AMETF’s with exposure to Cytori Therapeutics, Inc. : July 19, 2016 -
07/19/16 09:39 AMCytori Therapeutics Inc (CYTX) Broker Price Targets For The Coming Week - Fiscal Standard
07/19/16 09:39 AMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy™ Phase I Trial Reports Maxillofacial Bone ... - Smarter Analyst
07/19/16 06:02 AM7:02 am Cytori Therapeutics announces the publication of the results from a Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation -
07/19/16 06:00 AMCytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration - [Business Wire] - Cytori Therapeutics, Inc. announced today the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation.
07/16/16 04:27 AMShares Experiencing a Downtrend: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - TGP
07/15/16 02:33 PMHow Analysts Feel About Cytori Therapeutics Inc (NASDAQ:CYTX)? - Press Telegraph
07/14/16 09:03 PMSabby Management LLC Decreased Stake in Cytori Therapeutics INC (NASDAQ:CYTX) by $9.84 Million as Shares ... - Press Telegraph
07/14/16 04:26 PMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and -
07/14/16 06:17 AMCytori Therapeutics Inc Stock Momentum Hits Extreme Weakness - CML News
07/14/16 06:17 AMCytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Increased By 58.61% - Consumer Eagle
07/14/16 06:17 AMInsiders Increasing Positions in: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Press Telegraph
07/13/16 09:37 AMMost Active Healthcare Stocks- AbbVie Inc. (NYSE:ABBV), Cytori Therapeutics (NASDAQ:CYTX) - Seneca Globe
07/10/16 08:05 AMCytori Therapeutics DE (NASDAQ:CYTX) Sellers Increased By 58.61% Their Shorts - Engelwood Daily
07/10/16 08:05 AMNext Weeks Broker Price Targets For Cytori Therapeutics Inc (CYTX) - Fiscal Standard
07/08/16 08:33 PMInstitutional Investor Sentiment About Cytori Therapeutics Inc (NASDAQ:CYTX) Up - Press Telegraph
07/07/16 03:33 PMHeightened Volatility Check on: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Engelwood Daily
06/30/16 08:56 PMCytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Increased 58.61% After Market Selling - Engelwood Daily
06/30/16 08:56 PMRecently Issued Stock Ratings For Cytori Therapeutics Inc (CYTX) - Fiscal Standard
06/28/16 08:38 PMBroker Outlook For The Week Ahead Cytori Therapeutics Inc (CYTX) - Fiscal Standard
06/28/16 03:29 PMCytori: Tokyo OA Clinic Receives Approval to use Cytori Cell Therapy - RTT News
06/28/16 08:25 AMCytori Therapeutics' (CYTX) Cell Therapy for Knee Osteoarthritis Approved for Clinical Use in Japan
06/28/16 08:25 AMCytori Publishes ATHENA Trial Data For Chronic Ischemic Cardiovascular Disease
06/28/16 06:11 AMCytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease - [at noodls] - Data and Manuscript Now Published and Available Online SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the results from the ATHENA Trials have been published ...
06/27/16 08:02 AMTrader's Watch List: Cytori Therapeutics, Inc. (NASDAQ:CYTX), Mattel, Inc. (NASDAQ:MAT), Balchem Corp. (NASDAQ ... - KC Register
06/27/16 08:02 AMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy Receives Limited Approval for Osteoarthritis ... - Smarter Analyst
06/27/16 04:10 AMCytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan - [at noodls] - Tokyo OA Clinic Receives Their First Approval Under New Law SAN DIEGO & TOKYO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the use of Cytori Cell Therapy™ was approved ...
06/26/16 08:36 AMCytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Increased By 58.61% - Press Telegraph
06/23/16 08:14 AMNew Broker Ratings For Cytori Therapeutics Inc (CYTX) - FTSE News
06/20/16 01:18 PMETF’s with exposure to Cytori Therapeutics, Inc. : June 20, 2016 -
06/18/16 03:15 PMCytori Therapeutics Inc (CYTX) Drops 5.56% on June 16 - Equities.com
06/15/16 04:09 PMCytori Closes Rights Offering for Gross Proceeds of $17.1 Million - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. ('Cytori' or the 'Company') (NASDAQ: CYTX) announced today the closing of its rights offering ('Rights Offering') to subscribe for units at a subscription ...
06/15/16 04:07 PMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/15/16 03:35 PMCytori announces expiration of rights offering - Seeking Alpha
06/15/16 03:35 PMHC Stocks Impression: Cytori Therapeutics Inc (NASDAQ:CYTX), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release)
06/13/16 03:21 PMCytori Therapeutics (CYTX) Slides on Expiration of Rights
06/13/16 09:37 AM10 Stocks Moving In Monday's Pre-Market Session
06/13/16 09:37 AMCytori Therapeutics expects US$17.1mln from share issue
06/13/16 06:19 AMCytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. ('Cytori' or the 'Company') (NASDAQ: CYTX) announced today that the subscription period for its previously announced rights offering (the 'offering') ...
06/10/16 03:39 PMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy Leads to Improved Function and Reduced ... - Smarter Analyst
06/10/16 06:19 AMCytori Cell Therapy™ Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model - [at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urologyof a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) ...
06/09/16 10:49 AMWhich way Cytori Therapeutics, Inc. (NASDAQ:CYTX) earnings may go - iStreetWire
06/08/16 10:16 AMCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc To Present Twelve Month Pilot Trial Data of Cytori® Cell ... - Smarter Analyst
06/07/16 03:38 PMStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Enrollment Completion in US Phase III ... - Smarter Analyst

Social

About Cytori Therapeutics

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CYTX
  • CUSIP: 23283K10
Key Metrics:
  • Previous Close: $2.05
  • 50 Day Moving Average: $2.07
  • 200 Day Moving Average: $2.83
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $27.33M
  • Beta: 2.57
  • Current Year EPS Consensus Estimate: $-1.59 EPS
  • Next Year EPS Consensus Estimate: $-1.45 EPS
Additional Links:
Cytori Therapeutics (NASDAQ:CYTX) Chart for Friday, July, 29, 2016